KALA BIO, Inc.
KALA
Key stats
- Open
- 0.17
- Day high
- 0.17
- Day low
- 0.16
- Previous close
- 0.17
- Volume
- 384.8K
- VWAP
- 0.16
- 52-week high
- 95.50
- 52-week low
- 0.11
- Market cap
- 3.31M
- Shares out
- 19.34M
- Employees
- 6
- Listed
- 2017
About KALA BIO, Inc.
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
PHARMACEUTICAL PREPARATIONS · ARLINGTON, MA · kalarx.com
Quarterly results
Massive · Aug 19, 2026| Q2 2026 to Jun 30, 2026 | Q1 2026 to Mar 31, 2026 | Q4 2025 to Dec 31, 2025 | Q3 2025 to Sep 30, 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| Operating income | −$1.72M | −$1.80M | −$10.22M | −$7.24M |
| Net income | −$1.58M | −$1.62M | $686.0K | −$7.56M |
| Diluted EPS | -21.32 | -0.14 | 2.70 | -53.50 |
| Operating cash flow | −$1.53M | −$2.90M | −$4.56M | −$10.88M |
| Assets | $10.58M | $12.32M | $9.49M | $25.02M |
| Liabilities | $1.54M | $1.56M | $2.49M | $33.69M |
| Equity | $9.04M | $10.76M | $7.00M | −$8.66M |
Technicals
Massive · Nov 12, 2026- 50-day average0.34
- 200-day average5.45
- RSI (14 days)29.5
Short interest
Massive · Oct 30, 2026- Oct 30, 2026382.8K shares · 1.8 days to cover
- Oct 15, 2026539.4K shares · 1.0 days to cover
- Sep 30, 20261.36M shares · 1.0 days to cover
- Sep 15, 2026445.4K shares · 1.0 days to cover
Splits
Massive · Nov 16, 2026- Nov 16, 20261-for-30
- May 11, 20261-for-50
- Oct 21, 20221-for-50
- Aug 26, 20221.001-for-1
News coverage
No stories about KALA BIO, Inc. right now.